Intellia Therapeutics, Inc (NTLA) News
Latest headlines that mention NTLA, newest first · each headline opens the original publisher
- Last price
- $11.65
- Day change
- -1.60%
- Next earnings
- 2026-11-05
NTLA headlines
latest coverageLonvo-z Phase III trial met primary endpoint with 87% attack reduction versus placebo.
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.
Intellia stock surged Monday on promising results for the biotech company's gene-editing approach to a deadly swelling disorder. The post Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem? appeared first on Investor's Business Daily .
Also mentioned with NTLA
30d
Headlines that tag both tickers
NTLA news alerts
Get an alert by email or push when a new headline mentions NTLA.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.